Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? (Q33915293)

30 July 2017

1 reference

title

Bladder tumor markers: from hematuria to molecular diagnostics--where do we stand? (English)

1 reference

30 July 2017

1 reference

Samir P Shirodkar

1 reference

30 July 2017

Vinata B Lokeshwar

series ordinal

1 reference

30 July 2017

publication date

1 July 2008

1 reference

Expert Review of Anticancer Therapy

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

1111-1123

1 reference

Loss of telomeric DNA during aging may predispose cells to cancer (review).

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin: a promising biomarker for detection and prognosis of bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Detection of bladder cancer from the urine using fluorescence in situ hybridization technique.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

p53 and retinoblastoma pathways in bladder cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Molecular alterations associated with bladder cancer progression

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin expression is associated with bladder cancer presence, stage, progression, and mortality

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin: a promising tumor biomarker

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Defining optimal therapy for muscle invasive bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Urinary bladder tumor markers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Urothelial cancer biomarkers for detection and surveillance

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

P53 as a prognostic marker for bladder cancer: a meta-analysis and review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Evaluation of the patient with hematuria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Comparison of the ImmunoCyt test and urinary cytology with other urine tests in the detection and surveillance of bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

The health economics of bladder cancer: a comprehensive review of the published literature.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Improved detection of urothelial carcinomas with fluorescence immunocytochemistry (uCyt+ assay) and urinary cytology: results of a French Prospective Multicenter Study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Adherence to Surveillance Among Patients With Superficial Bladder Cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Bladder cancer: epidemiology, diagnosis, and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Current and future perspectives in advanced bladder cancer: is there a new standard?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Interphase fluorescence in-situ hybridization in the diagnosis of bladder cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

HA-HAase urine test. A sensitive and specific method for detecting bladder cancer and evaluating its grade

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Urine cytology. It is still the gold standard for screening?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Evaluation of asymptomatic microscopic hematuria

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Complement factor H or a related protein is a marker for transitional cell cancer of the bladder.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Alterations of tumor suppressor genes in bladder cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Microsatellite instability and DNA mismatch repair in human cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Telomeres, Telomerase, and Immortality

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Urine cytology in bladder tumors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Telomeres — what's new at the end?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Cytokeratin Shedding in Urine as a Biological Marker for Bladder Cancer: Monoclonal Antibody-Based Evaluation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.

5 July 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Usefulness of urinary NMP22 to detect tumor recurrence of superficial bladder cancer after transurethral resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

A side by side comparison of cytology and biomarkers for bladder cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Quantitative analysis of survivin mRNA expression in urine and tumor tissue of bladder cancer patients and its potential relevance for disease detection and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Functional characterization of the bladder cancer marker, BLCA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Quantitative evaluation of telomerase subunits in urine as biomarkers for noninvasive detection of bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Prognostic value of p53 for high risk superficial bladder cancer with long-term followup

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: a utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Natural history, recurrence, and progression in superficial bladder cancer.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Highly specific urine-based marker of bladder cancer

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Survivin protein expression positively correlated with proliferative activity of cancer cells in bladder cancer.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5515477

Non-invasive molecular detection of bladder cancer recurrence

29 October 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.7.1111

Immunocytology in the assessment of patients with asymptomatic hematuria

21 January 2018

1 reference

12 December 2020

Detection of bladder cancer recurrence by microsatellite analysis of urine

1 reference

12 December 2020

Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1

1 reference

12 December 2020

Multiplex Polymerase Chain Reaction for Microsatellite Analysis of Urine Sediment Cells: A Rapid and Inexpensive Method for Diagnosing and Monitoring Superficial Transitional Bladder Cell Carcinoma

1 reference

12 December 2020

Genetic alterations in bladder cancer

1 reference

12 December 2020

Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors

1 reference

12 December 2020

Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor

1 reference

12 December 2020

Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer

1 reference

12 December 2020

Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients

1 reference

12 December 2020

Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China

1 reference

12 December 2020

ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma

1 reference

12 December 2020

The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies

1 reference

12 December 2020

Fluorescence in situ hybridization for detecting transitional cell carcinoma: implications for clinical practice

1 reference

12 December 2020

Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract

1 reference

12 December 2020

Cytokeratin 20: a new marker for early detection of bladder cell carcinoma?

1 reference

12 December 2020

Surveillance for recurrent bladder cancer using a point-of-care proteomic assay

1 reference

12 December 2020

Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4

1 reference

12 December 2020

Urine Telomerase Activity for the Detection of Bladder Cancer in Females

1 reference

12 December 2020

Molecular markers in bladder cancer

1 reference

12 December 2020

Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization

1 reference

12 December 2020

Telomerase activity in normal leukocytes and in hematologic malignancies

1 reference

12 December 2020

Clinical decisions for treatment of different staged bladder cancer based on multitarget fluorescence in situ hybridization assays?

1 reference

12 December 2020

Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer

1 reference

12 December 2020

Survival experience of black patients and white patients with bladder carcinoma

1 reference

12 December 2020

Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice

1 reference

12 December 2020

Detection of telomerase in urine by 3 methods: evaluation of diagnostic accuracy for bladder cancer

1 reference

12 December 2020

NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study

1 reference

12 December 2020

Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder

1 reference

12 December 2020

Initial Evaluation of Cyfra 21-1 Diagnostic Performances as a Urinary Marker in Bladder Transitional Cell Carcinoma

1 reference

12 December 2020

Clinical application of NMP22 and urinary cytology in patients with hematuria or a history of urothelial carcinoma

1 reference

12 December 2020

Noninvasive detection of bladder cancer with the BTA stat test

1 reference

12 December 2020

Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract

1 reference

12 December 2020

Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods

1 reference

12 December 2020

Role of uCyt+ in the detection and surveillance of urothelial carcinoma

1 reference

12 December 2020

Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis

1 reference

12 December 2020

Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment

1 reference

12 December 2020

Bladder tumor antigen stat test in non-urothelial malignant urologic conditions

1 reference

12 December 2020

Long-term outcome of hematuria home screening for bladder cancer in men

1 reference

12 December 2020

Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat

1 reference

12 December 2020

Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer

1 reference

12 December 2020

Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma

1 reference

12 December 2020

Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings

1 reference

12 December 2020

Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors

1 reference

12 December 2020

Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade

1 reference

12 December 2020

Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder

1 reference

12 December 2020

Detection of bladder cancer using a point-of-care proteomic assay

1 reference

12 December 2020

Noninvasive diagnosis of bladder cancer by detection of matrix metalloproteinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) in urine

1 reference

12 December 2020

Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests

1 reference

12 December 2020

Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer

1 reference

12 December 2020

Multiple mucosal biopsies and postoperative urinary cytology in patients with bladder cancer

1 reference

12 December 2020

Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis

1 reference

12 December 2020

The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma

1 reference

12 December 2020

Comparison of seven screening methods in the diagnosis of bladder cancer

1 reference

12 December 2020

Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma

1 reference

12 December 2020

Performance characteristics of a new monoclonal antibody test for bladder cancer: ImmunoCyt trade mark

1 reference

12 December 2020

Use of urinary biomarkers for bladder cancer surveillance: patient perspectives

1 reference

12 December 2020

Urine detection of survivin and diagnosis of bladder cancer

1 reference

12 December 2020

Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer

1 reference

12 December 2020

Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis

1 reference

12 December 2020

Molecular followup of newly diagnosed bladder cancer using urine samples

1 reference

12 December 2020

Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers

1 reference

12 December 2020

Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo

1 reference

12 December 2020

Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer

1 reference

12 December 2020

10.1586/14737140.8.7.1111

Identifiers

DOI

1 reference

30 July 2017

1 reference

30 July 2017

1 reference